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Introduction. 
 
A dominantly inherited familial form of motor neuron disease characterized in a large 
Brazilian family was recently shown to be associated with a mis-sense mutation in the 
human vapB gene (1).  Affected individuals suffer from three different pathological 
conditions; a late on-set slowly progressing spinal muscular atrophy (SMA), a slowly 
progressing late on-set atypical amyotrophic lateral sclerosis ALS8, or a typical 
severe rapidly progressing ALS (2, 3).  Although familial forms of disease may 
represent less than 5% of the total incidences of ALS (4, 5), they exhibit the same 
phenotypic heterogeneity as the more common sporadic disease (6-8).  Information on 
the mechanistic basis of familial motor neuron diseases may, therefore, be relevant to 
all forms of motor neuron disease. 
 
The first VAP protein was identified in Aplysia californica from its interaction in a 
yeast two-hybrid screen with VAMP/Synaptobrevin, hence the nomenclature 
VAMP/Synaptobrevin Associated Protein (9).  VAP proteins are highly conserved, 
with homologous proteins found in all eukaryotes  (10-15). There are two mammalian 
genes VapA and VapB (16).  The proteins contain three prominent structural features; 
the N-terminal domain of approximately 120 amino acids is highly homologous to the 
nematode Major Sperm Protein (MSP) (17), the central domain is amphipathic and 
predicted to form a coiled-coil structure, and the C-terminal 20 amino acids are 
hydrophobic and act as an intracellular membrane anchor (13, 15, 16).  
The MSP domain binds to the “two phenylalanines in an acid tract”, or "FFAT" motif 
found in several cytoplasmic lipid binding proteins (18-20).  The structural basis of 
this interaction was recently determined for the MSP domain of VAPA (21).  Thus, 
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VAP proteins may act as docking sites for cytoplasmic factors to interact with the ER.  
VAP proteins may also act to maintain the structure of intracellular membranes such 
as the ER, by interacting with the cytoskeleton and mediating membrane trafficking 
(13, 15, 22). 
The disease-associated mutation in ALS8 is a C to T substitution within exon 
2 of the vapB gene replacing a proline residue with a serine in a highly conserved 
region of the protein.  The mutant protein, VAPBP56S, forms aggregates when 
expressed in cultured cell lines or primary hippocampal neurons (1).  The relationship 
of these aggregates to the pathological mechanism of the disease is not known.  It has 
been suggested that the presence of aggregates containing VAPBP56S may result in 
disruption of the proteosome, activation of ER stress responses, fragmentation of the 
Golgi apparatus, and induction of apoptosis (23).  Teuling et al., have also 
demonstrated that expression of VAPBP56S recruits the wild type protein into 
aggregates and causes disruption of ER structure (24). 
 
In this report we show that both VAPA and VAPB are ubiquitously expressed but at 
differing levels in different tissues and that they accumulate on overlapping but 
distinct regions of the ER.  Both VAPA and VAPB are shown to be capable of 
interacting with the ER stress regulated transcription factor ATF6, and over 
expression of VAPB or VAPBP56S attenuates the activity of an ATF6/XBP1 regulated 
promoter. This suggests that VAPB can have an inhibitory affect on ATF6 dependent 
transcription and that the disease associated mutant, VAPBP56S, has an enhanced 
inhibitory activity towards ATF6-dependent transcription compared to the wild-type 
protein. An interaction between VAP proteins and ATF6 may represent a previously 
uncharacterised mechanism of ER homeostatic and stress response regulation. 
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It is concluded that mis-regulation of ER stress response and homeostatic 
regulatory systems may contribute to the pathological mechanism of degenerative 
motor neuron disease associated with the VAPBP56S mutation. 
 
Results. 
VAPA and VAPB are expressed ubiquitously but at differing levels in different tissues. 
Immunoblot analysis of selected tissues from an adult male rat demonstrated that both 
VAPA and VAPB proteins are present in all tissues examined, but at different relative 
levels (Fig1A).   This is in agreement with the wide expression profile of mRNA 
published previously (13, 16, 25).  A second protein of slightly larger molecular 
weight is detected in the testis by VAPA anti-sera.  An additional, less abundant, 
protein of approximately 14kD is detected by both anti-serum.  The VAPB-related 
signal is a doublet, the expression of which is tightly restricted to the forebrain and 
cerebellum extracts, and not detected in the other tissues tested (Fig1A).  The 14kD 
VAPA-related polypeptide is more widely expressed and detectable in pancreas, liver, 
forebrain, lung and thymus, kidney and testis; low levels are seen in the cerebellum 
and no signal is detected in heart or skeletal muscle.  A peptide of similar size has 
been predicted from a splice variant of VAPB, termed VAPC.  However, the peptide 
used to generate the VAPB anti-serum is not present in VAPC (16), and the VAPA 
anti-sera does not cross react significantly with vapB-derived species (see 
Supplimentary Fig 1).  It is concluded that these smaller molecular weight 
immunoreactive species are most likely generated by proteolysis of the VAP proteins. 
It has been shown previously that both VAPA and VAPB are enriched on the ER 
membrane (13, 15, 21). A distinct sub-cellular distribution for the two proteins is seen 
by co-immunostaining of HEK293 cells (Fig. 1B).  Both proteins are localised in a 
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reticular pattern, but they exhibit only a modest level of co-localization.  This distinct 
sub-cellular distribution of VAPA and VAPB is most striking in skeletal muscle 
(Fig1C).  Fluorescent immunocytochemistry indicates a complementary distribution 
of VAPA and VAPB in the sarcoplasmic reticulum.  VAPA is enriched on the A-and 
H-bands and the Z-line, while VAPB is restricted to the I-band and T-system regions 
(Fig1D).  The I-band is enriched for IP3 receptors and RyR localise mainly at the T-
system (39), VAPA and VAPB may therefore, be associated with distinct intracellular 
calcium stores. 
 
Interactions of the VAP MSP domain. 
The ALS8- associated mutation in the VAPB protein lies within a highly conserved 
region of the MSP domain. In a previous series of experiments we had observed that, 
when expressed as an EGFP fusion protein, the MSP domains of both VAPA and 
VAPB formed intensely fluorescent, large intracellular aggregates, and were toxic to 
HEK293 and PC12 cell lines, and to primary cultures of rodent hippocampal neurons 
(Skehel, unpublished).  To investigate possible mechanisms of the MSP domain 
toxicity a yeast two-hybrid screen was done to identify potential MSP interacting 
proteins.  A sequence corresponding to amino acids 1-107 of mouse VAPA was used 
to screen a rat brain cDNA library.  In addition to a number of FFAT- and MSP 
domain-containing proteins, a partial clone of the ER stress regulated transcription 
factor ATF6 was identified (26).  
To characterize this interaction further, expression constructs for full length 
VAPA, VAPB and ATF6 were analysed by a fluorescent peptide complementation 
assay (27)(Fig 2).  In this assay, a fluorescent protein is generated from the two 
separate parts of a split GFP, termed Venus1 and Venus2, only by the association of 
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two test polypeptides expressed as fusion proteins.  A functional fluorescent protein is 
only generated when the two test proteins directly interact.  Although the initial yeast 
two-hybrid interaction was between a truncated form of ATF6 and the MSP domain 
of VAPA, an interaction between full-length forms of VAPA and VAPB with ATF6 
was readily detectable (Fig 2).  Similarly, the ALS8-associated mutant VAPBP56S was 
shown to be capable of interacting with ATF6 (Fig 2).  No interaction was detected 
between VAPA, VAPB or ATF6 when co-expressed with heterologous leucine 
zipper-Venus fusions.  The reconstitution of a fluorescent protein clearly indicates 
that VAPA and VAPB are capable of interacting with ATF6.  Similar results were 
also obtained with the converse Venus combinations, where ATF6 was expressed as a 
fusion with Venus 1, and the VAP proteins were fused to Venus 2 (data not 
shown)(27). 
Fluorescence analysis of HEK293 cells expressing EGFP-VAPB and FLAG-
tagged ATF6 shows extensive regions of co-localization on the ER, but also some 
complementary distribution (Fig 3).  The aggregates of EGFP-VAPBP56S show some 
but not extensive co-localization with ATF6, although we cannot discount that low 
antigen accessibility may contribute to reduced ATF6 detection in VAPBP56S 
aggregates.  Expression of VAPBP56S does not appear to cause gross disruption of 
ATF6 distribution in the ER (Fig 3).   
 
 
ATF6 is inhibited by VAPB and VAPBP56S. 
ATF6 is one of a family of transmembrane transcription factors (28).  It 
functions in a regulated transcription pathway involved in ER homeostasis and 
response to stress known as the Unfolded Protein Response (UPR)(29-31).  Upon 
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accumulation of unfolded proteins in the lumen of the ER, ATF6 translocates from 
the ER to the Golgi and is proteolyzed in turn by S1P and S2P.  This results in the 
release of the DNA binding and transcription transactivation domain of ATF6 from 
the ER membrane allowing it to enter the nucleus and activate transcription (26, 32).  
ATF6 appears to interact with several promoter elements (30, 33, 34). A 
synthetic promoter has been generated that acts as an ATF6/XBP1 dependent 
transcription reporter (30). To determine if the interaction with VAPB affects the 
ability of ATF6 to activate transcription, luciferase-based transient transcription 
assays were done using this ATF6/XBP1-dependent reporter of transcription (30). In 
HEK293 cells basal levels of transcription from this promoter are reduced by over-
expression of myc-tagged forms of VAPB or VAPBP56S (Fig 4a).  ATF6/XBP1-
mediated transcription activated by the glycosylation inhibitor, tunicamycin, was also 
significantly reduced by over expression of VAPB or VAP-BP56S(Fig 4a)(35, 36).  
Increasing levels of ATF6 by co-expression of a FLAG-tagged recombinant form of 
human ATF6 (37) increased basal and tunicamycin-induced expression from the 
ATF6/XBP1 reporter.  In both cases the elevated levels of ATF6/XBP1 dependent 
transcription were also reduced by over expression of either VAPB or VAPBP56S (Fig. 
4b). This effect requires the cytoplasmic domains of VAPB and does not appear to be 
a non-specific consequence of increasing levels of protein in the ER membrane since 
over expression of a DsRed fluorescent fusion protein of the C-terminal hydrophobic 
domain of VAPB does not reduce the basal or tunicamycin-induced expression from 
the ATF6/XBP1 reporter (Fig 4a and Supp. data S3).  Over expression of VAP 
proteins does not reduce expression levels of luciferase directed from a CMV 
promoter, therefore the repressive affect on the ATF6/XBP1 reporter is unlikely to be 
a the result of a general repression of transcription (Supp. data S4).   
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A similar inhibitory affect was also seen in the motor neuron derived cell line 
NSC34 (Fig4 c,d).  In NSC34 cells basal levels of expression from the ATF6/XBP1 
reporter are less than in HEK293, perhaps indicating lower levels of endogenous 
ATF6. 
Consistent with the inhibitory affect seen by over expression of VAPB, 
siRNA-mediated reduction of endogenous VAPB results in an increase of basal and 
induced levels of ATF6/XBP1-dependent transcription (Fig 5). 
When equal amounts of expression plasmid DNA for VAPB and VAPBP56S 
were used for cell-transfections, the overall level of attenuation was similar between 
the wild type and mutant forms of VAPB (Fig 4).  Immunoblot analysis of total 
protein from transfected cells, however, indicated that the mutant protein, VAPBP56S -
myc, accumulated to significantly lower levels, reaching only 20% of the level of wild 
type protein. (Fig 6).  This suggests that VAPBP56S-myc may exert a stronger 
inhibition on ATF6 than the wild type VAPB-myc, since a similar level of inhibition 
is achieved from a lower amount of protein.  The difference in protein levels is less 
pronounced when VAPB and VAPBP56S are expressed as EGFP fusion proteins (Fig 
6), which indicates that the presence of the GFP moiety may have a stabilizing affect 
on VAP-BP56S.  Consistent with this, the inhibition of ATF6/XBP1-dependent 
transcription is more pronounced for EGFP-VAPBP56S than EGFP-VAPB (Fig 6).  
Thus VAPBP56S appears to have a significantly greater inhibitory affect on ATF6 
mediated transcription than wild type VAPB.  These results suggest that mis-
regulation of ER stress responses may be important for the pathological affect of 
VAPBP56S that leads to motor neuron degeneration. 
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Discussion. 
The identification of a mutated gene responsible for a familial form of motor neuron 
disease greatly facilitates molecular and cellular studies of potential disease 
mechanisms. Understanding the cellular function of VAPB may indicate what 
molecular and cellular events are associated with the disease process of ALS8.  It is 
likely that this information will be of relevance to both the inherited condition and the 
more common sporadic forms of disease. 
Previous studies have demonstrated a role for VAP proteins on the ER.  The 
N-terminal MSP domain contains an FFAT-motif binding site (21).  This interaction 
has been shown to localize a number of cytoplasmic lipid-binding proteins to the ER 
and ER-derived membranes (18-20, 38).  FFAT-dependent interactions between 
VAPA and Nir2 and 3 have also been shown to affect the gross structure of the ER 
(22).  Both VAPA and VAPB appear to be expressed at different relative levels in 
specific tissues ((25) (16)and this study).  Both proteins are enriched on the ER and 
co-localise to a large extent (24).  There are, however, many regions where the two 
proteins do not co-localize, suggesting they are present in distinct functional regions 
of the ER. This is most clearly seen in skeletal muscle where VAPA is enriched 
within the A and H bands and Z-line, whereas VAPB is seen predominantly in the I-
bands and T-region.  The localization of VAPA is similar to that of the IP3 receptor 
(39), whereas VAPB more closely resembles the distribution of Ryanodine receptors 
(40).  Any disruption of VAPB function caused by the P56S mutation associated with 
ALS8 might, therefore, affect intracellular Ca2+ storage and Ca2+ signalling capacities.  
Intracellular Ca2+ levels have been implicated in many degenerative conditions 
(reviewed in (41)), and inhibition of Ryanodine receptor activity has been recently 
suggested as a possible pathological mechanism for motor neuron disease (42).  
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The proline residue at codon 56 within the MSP domain does not appear to contribute 
directly to FFAT-binding but co-immunoprecipitation of FFAT-containing proteins is 
reduced for VAPBP56S (24).  Perturbation of FFAT-dependent association with the ER 
could disrupt the sorting of lipids within and between cellular membranes (19, 20).  A 
phosphoinositide-binding activity has been identified in the MSP domain of the yeast 
protein SCS2, that is a homologue of VAPA and VAPB (43). 
 
Disruption of the MSP domain in VAPBP56S could affect a similar activity in the 
mammalian proteins.   Changes in membrane composition have been suggested as a 
cause of neurodegeneration (44), and hyperlipidemia is one of the clinical effects 
reported for VAPBP56S families (3).  Disruption of ER and Golgi structure and/or 
function has been suggested previously as a possible pathological mechanism for 
degenerative diseases of neurons (45-47).  More recently ER stress in particular has 
been associated with sporadic and experimental models of motor neuron disease (48-
50), and neurodegeneration in general (for reviews see(46, 47, 51)).  A recent report 
has also suggested that VAPB levels may induce the ER Unfolded Protein Response 
by affecting the activity of IRE1(23).  In this report we show that VAPA and VAPB 
can interact directly with the ER-localized transcription factor ATF6.  Moreover, 
increasing the expression of VAPB attenuates the activity of ATF6, while reducing 
VAPB levels enhance ATF6-dependent transcription.  Over expression of the mutant 
protein VAPBP56S appears to attenuate the activity of ATF6 more profoundly than 
does wild type VAPB.  The proteinaceous aggregates formed by VAPBP56S do not 
appear to sequester ATF6 to a significant extent.  The enhanced inhibitory affect of 
VAPBP56S levels on ATF6 activity may not, therefore, be due simply to a reduction in 
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available ATF6.  There are a number of stages in the activation of ATF6 that VAPB 
could influence. In response to accumulation of unfolded protein in the ER lumen 
ATF6 translocates from the ER to the Golgi.  There it is sequentially processed by 
S1P and S2P proteases to release a C-terminal portion of the protein containing DNA 
binding and transactivation domains (32).  The lumental N-terminal domain of ATF6 
is required to detect the accumulation of unfolded proteins in the lumen of the ER.  As 
VAPB has very little luminal structure it is unlikely to directly inhibit the ability of 
ATF6 to detect ER stress.  Over expression of VAPB can disrupt membrane 
trafficking and so may indirectly inhibit the activation of ATF6 by reducing the 
translocation of ATF6 to the Golgi (15).  Alternatively, VAP proteins might directly 
inhibit the translocation of ATF6 to the Golgi.  It is also possible that VAP acts after 
translocation of ATF6 to the Golgi by a mechanism similar to that of Nucleobindin1 
which represses S1P activation of ATF6 (53).   
 VAPB may act at the level of transcription.  The yeast VAP homologue 
SCS2, originally identified as a suppressor of inositol auxotrophy, has been shown to 
localise activated genes to the nuclear membrane via an interaction with a FFAT 
domain-containing protein, Opi1 (10, 54).  The localization to the nuclear membrane 
was essential for gene expression (54).   If an analogous situation existed in 
mammals, over expression of VAPB could directly affect the activity of ATF6 at 
promoters adjacent to the nuclear membrane.  
 
A regulatory role for VAP proteins on the surface of the ER. 
The UPR and ERAD systems respond to the environment of the lumen of the ER.  
Perhaps the interaction between the VAP proteins and ATF6 represents an additional 
element of ER regulation that responds to levels of proteins associating with the 
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surface of the ER, or to proteins that do not have significant amounts of luminal 
structure.  
VAP proteins interact with a broad range of other coiled-coil containing 
proteins such as VAMP/Synaptobrevin and syntaxin (12).  If interactions of the 
coiled/coil domain also affected the MSP domain-dependent inhibition of ATF6, they 
could enable the levels of membrane proteins on the surface of the ER to activate 
ATF6.  
 
VAP proteins and Hepatitis C virus replication. 
The Hepatitis C virus has exploited potential structural and regulatory 
functions of the VAP proteins.  Hepatitis C replicates in association with the ER.  
Two of the viral proteins required for this association, NS5A and NS5B, can bind to 
both VAPA and B, interacting with the coiled-coil and MSP domains respectively 
(56, 57).  Disrupting these interactions or down regulating VAPA and VAPB protein 
levels inhibits virus replication (57, 58).  Hepatitis C protein expression can also 
induce ER stress, activating both ATF6 and XBP1.  This does not lead to a full 
Unfolded Protein Response (59, 60), and it has been suggested that mis-regulation of 
the ER stress response may in someway favour viral replication (60).  Perhaps a 
similar mechanism may contribute to the pathogenesis of VAPBP56S.  The mutant 
protein could lead to a mis-regulation of ER stress regulatory pathways via aberrant 
ATF6 activity.  Such mis-regulation could also have a role in the pathological affects 
of Hepatitis C infection.  
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ATF6 activity and neurodegeneration. 
The increased level of ATF6 inhibition by VAPP56S suggests that a possible 
pathological mechanism for ALS8 is mis-function of homeostatic regulatory systems 
of the ER.  Kanekura et al., recently demonstrated that increased VAPB levels could 
induce the unfolded protein response as indicated by activation of XBP1, and that the 
affect of VAPBP56S was to diminish this activation (23).  Our study suggests that VAP 
proteins can also affect the activity of ATF6, and that the mutation VAPBP56S may, 
have a greater effect than the wild type protein VAPB.  From gene transcription 
analysis on the UPR in c.elegans it has been shown that ATF6 mainly contributes to 
tonic levels of gene expression (61).  In mammals ATF6 appears to have a more 
extensive role in the ER stress response, where it is required for the induced 
expression of principal ER chaperones, and also acts as a heterodimer with XBP1 to 
induce components of the ER associated degradation pathway  (ERAD)(29). 
 
The direct interaction between VAP proteins and ATF6 represents a previously 
uncharacterised mechanism for the regulation of transcriptional responses made to 
changes in ER metabolism.   Over all, VAP proteins may have structural and 
regulatory functions based on interactions of the MSP domain. The pathological 
mechanism in ALS8, therefore, may be the result of an inability to deal appropriately 
with different forms of ER stress.  
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Materials and Methods.
 
Antisera.  VAPB specific anti-serum was raised in sheep to a Multi Antigenic Peptide 
(MAP) form of a peptide corresponding to amino acids 174-189 of mouse VAPB 
(Alta Bioscience).  This sequence is identical in rats and mice.  The serum was 
affinity purified using the immunizing peptide.  The VAPA anti-serum has been 
described previously (13).  Anti-myc was monoclonal 9E10 and anti-FLAG was M2 
(Sigma). 
 
 
Muscle staining 
Muscle tissue was fixed in 0.1M PBS containing 4% paraformaldehyde for 1-2 hours. 
Muscles were blocked in 4% BSA and 0.5% Triton-X (both Sigma) in PBS for 30 
min before incubation in primary antibodies overnight at 4ºC. The primary antibodies 
used were sheep anti-VAPB (1:200) and rabbit anti-VAPA, (1:300). After washing 
for 30 min in blocking solution, muscles were incubated for 4-5 hours in PBS 
containing secondary antibodies. The secondary antibodies used were Donkey anti-
Sheep Cy2 (1:100, Jackson Laboratories) and Donkey anti-Rabbit Cy3 (1:100, 
Jackson Laboratories). After a 2 hr wash in PBS, muscles were mounted on glass 
slides in mowoil mounting medium (2.4g mowoil (Poly vinyl Alcohol, Calbiochem), 
6g glycerol, 2.5% 1,4-diazobicyclo-octane (DABCO, antifade, Sigma), 12 ml 200mM 
Tris (pH 8,5)). Preabsorption experiments for VAPB were performed using a 100-fold 
excess of the VAPB peptide (~40mg/ml). This was added to the antibody and left at 
room temperature for 1 hour before proceeding with the remainder of the 
immunocytochemistry protocol detailed above. 
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Preparations were analysed using a laser confocal scanning microscope (Biorad 
Radiance 2000). The strobing function was always enabled to prevent signal bleeding 
through from one channel to another. Confocal z-series were merged using 
Lasersharp (Biorad) software.  All images were analysed and prepared for 
presentation in Adobe Photoshop. 
 
 
Cell Staining
 
HEK293 cells grown on poly-D-lysine coated cover slips were fixed in 3% 
paraformaldehyde, 0.03%glutaraldehyde (w/v) in PBS, at room temperature for 
20mins.  Fixative was quenched and cells permeablized with a solution of 50mM 
NH4Cl, 0.2% (w/v) Saponin (Sigma), for 15 minutes at room temperature.  Cells were 
washed, and antibodies diluted in a solution containing 0.2% (w/v) fish skin gelatin 
(Sigma G-7765), 0.02% saponin, in PBS.  Inverted cover slips were mounted in 
Mowoil, and examined on a Zeiss Imager.Z1 microscope fitted with a LSM 510 Meta 
confocal excitation/acquisition system.     
     
Peptide complementation 
Full length coding sequences for mouse VAPA, VAPB, VAPAP56S, VAPBP56S, and 
human ATF6a (NM_007348) were amplified in a PCR that introduced flanking BspEI 
and XbaI, or NotI and ClaI restriction sites, and sub-cloned into pcDNA3.1(zeo)-
Venus[1] or pcDNA3.1(zeo)-Venus[2] respectively (27).  HEK293 were transfected 
using Lipofectamine 2000 (Invitrogen). For each transfection 200ng of total DNA 
was used. Images of living cells were acquired 24 hours after transfection on an 
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Olympus IX70 fluorescence microscope using Openlab software (Improvision).  
Representative images are shown. 
 
 
Transcription assay 
HEK293 or NSC-34 cells were grown in Dulbecco’s Modified Eagle’s Medium 
supplemented with 10% fetal bovine serum. Cells were transfected using 
Lipofectamine2000 (Invitrogen). Each transfection mixture contained 300 ng of 
p5xATF6-GL3 (30) and 100ng of the internal control renilla luciferase reporter, pRL-
TK.  VAPB and VAPBP56S were expressed as EGFP-fusion proteins derived from 
pEGFP-C1 (Clontech), or as myc epitope tagged fusion proteins where the EGFP 
coding sequence was replaced with a myc epitope coding sequence.  The total amount 
of DNA per transfection was 500ng .  ATF6 was over expressed as a FLAG-tagged 
fusion protein from pCMV-ATF6-3xFLAG7.1 (62).  100ng of each VAPB and ATF6 
expression plasmid was used, with the total amout of DNA in each transfection made 
up to 600ng with the vector pEGFP-C3 (Clontech).  24 hours after transfection ER 
stress was induced for 12 hours with 2mg/ml tunicamycin (Calbiochem). Cells were 
then lysed and assayed for firefly and renilla luciferase activity using the Dual GloTM 
Luciferase Assay System (Promega). Firefly and renilla luminescence were measured 
using a FLUOstar OPTIMA micro-plate reader (BMG LABTECH). Firefly luciferase 
luminescence values are normalised to renilla firefly luminescence values and are 
averages of 4 experiments with S.E. 
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siRNA transfection 
106 HEK293 cells were nucleofected with 200 pMoles of VAPB siRNA (Quiagen) or 
a control GFP-siRNA (Dharmacon) using the Amaxa Biosystems nucleofector.  24 
hours after nuclofection, cells were transfected with p5xATF6-GL3 and pRLTK as 
described above. After a further 24 hours, cells were treated with 2 µg/ml 
Tunicamycin (Calbiochem) for 12 hours and then assayed for luciferase activity as 
above. 
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Figure legends. 
Figure 1A. Detection of VAPA and VAPB in different tissues. Anti-peptide anti-
serum was raised to residues 174-189 of  mouse VAPB.  In the tissues indicated the 
predominant immunoreactivity is at approximately 27kD, in agreement with the 
molecular weight predicted from the cDNA.  Both VAPA and VAPB are expressed 
widely but at different levels.  A faster migrating VAPB-related doublet signal of 
approximately 14kD is clearly detected in forebrain and cerebellum protein extracts. 
The immunoblot is deliberately over exposed to demonstrate the restricted nature of 
this expression pattern.  A faster migrating immunoreactive species of approximately 
14kD is also seen with VAPA anti-sera, however, in contrast to that seen for VAPB, 
this species is detectable in pancreas, liver, forebrain, lung and thymus, kidney and 
testis; low levels are seen in the cerebellum and no signal is detected in Heart or 
skeletal muscle.   
 
 
 
Figure 1B.  VAPA and VAPB are expressed in distinct reticular patterns.  Indirect 
immunoflouroescence analysis of VAPA and VAPB in HEK293 cells reveals a 
reticular pattern of expression, but detects very little co-localization of the two 
proteins.  VAPA is shown in red and VAPB in green. 
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Figure 1C. VAPA and VAPB are enriched in a complementary distribution in skeletal 
muscle. Confocal micrographs of an immunocytochemically labelled transversus 
abdominis muscle from a 2 month old mouse (VAPA in red, VAPB in green).  The 
staining patterns of VAPB were consistent with it being located around putative I—
band and T-system regions. In contrast, VAPA was absent from these regions, and 
appeared to be more strongly expressed in the regions associated with A- and H-bands 
and Z-lines.  A pseudo-coloured electron micrograph is shown to indicate the position 
of VAPA and VAPB staining in relation to the structure of a muscle sarcomere 
 
 
Figure 2. Peptide complementation assay for the interaction of VAPA and VAPB with 
ATF6.   The coding sequences of mouse VAPA, VAPB and VAPBP56S were 
expressed in HEK293 cells as fusion proteins with a truncated non- fluorescent form 
of YFP, Venus 1 (Remy et al., 2002).  These proteins were co-expressed with the 
complementary ATF6-Venus 2fusion protein.  Fluorescence indicates reconstitution 
of a functional YFP and therefore a direct interaction of VAPA and VAPB with 
ATF6. Wild type VAPB and mutant VAPBP56S are capable of interacting with ATF6.  
Controls in which a homodimerizing leucine zipper peptide was expressed as either a 
Venus 1 or Venus 2 fusion proteins show no fluorescence when expressed with the 
complementary VAP or ATF6 fusion proteins. Bright field or fluorescence images 
were acquired from live cells through cell culture plastic.  
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Figure 3.  Co-localization of VAPB and ATF6.  HEK293 cells were transfected with 
FLAG-ATF6, EGFP-VAPB and EGFP-VAPBP56S.  In colour plates FLAG-ATF6 is 
shown in red and EGFP-VAPB or EGFP-VAPBP56S is in green.  There is extensive, 
but not total co-localisation of VAPB and ATF6 in a reticular distribution.  ATF6 co-
localises with the aggregates formed by VAPBP56S, but not in a punctate pattern.  Note 
that VAPBP56S does not cause a gross change in the distribution of ATF6.  
 
 
Figure 4.  VAPB and VAPBP56S inhibit transcription from an ATF6 regulated 
transcription reporter.  (A) HEK293 were transfected with a reporter plasmid 
containing the luciferase cDNA regulated by five ATF6/XBP1 binding sites, 
pGL3(5X)ATF6.  Cell cultures were co-transfected with expression plasmids 
encoding VAPB or VAPBP56S as myc-tagged fusion proteins (VAPB-myc and 
VAPBP56S-myc) or a monomeric red fluorescent fusion protein containing the C-
terminal 41 amino acids of VAPB (VAPB-Cterm).  Where indicated cultures were 
treated for 12 hours with 2mg.ml Tunicamycin to induce ER stress.  VAPB and 
VAPBP56S reduce constitutive levels of ATF6/XBP1 activity, while VAPB-Cterm had 
no effect.  (B) Over expression of ATF6 as a ATF6-FLAG fusion protein increased 
basal and tunicamycin-induced activity of the ATF6/XBP1 reporter gene, but in both 
cases levels of activity were reduced by co-expression of VAPB-myc or VAPBP56S-
myc.  (C and D) The same experiments using the motor neuron-like cell line NSC34 
gave similar results. 
 
Figure 5.  VAPB siRNA reduces the levels of endogenous VAPB and increases basal 
ATF6/XBP1-dependent transcription. (A) Immunoblot analysis of HEK293 cells 
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nucleofected with VAPB siRNA or GFP siRNA and non-transfected cells shows a 
25% reduction in levels of endogenous VAPB when treated with VAPB siRNA and 
no reduction in GFP siRNA treated cells. *A 60 KD non-specific band from longer 
exposures of the immunoblot serves as a loading control. Band intensities were 
measured using ImageJ (NIH). (B) siRNA to VAPB increases basal, and tunicamycin-
induced, transcription and from an ATF6/XBP1-regulated transcription promoter. 
 
Figure 6. VAPBP56S accumulates to lower levels than VAPB.  Immunoblot analysis of 
HEK293 cells expressing myc or GFP-tagged forms of VAPB and VAPBP56S. 
Duplicate samples are shown, and relative levels expressed as a histogram of signal 
intensities.  As both myc and GFP fusion proteins VAPBP56S accumulates to lower 
levels than VAPB. VAPBP56S-myc is approximately 15% the level of VAPB-myc, and 
VAPBP56S-GFP is approximately 50% the level of VAPB-GFP.  The GFP moiety 
appears to have a stabilising affect on the levels of mutant protein, allowing it to 
accumulate to higher levels than the myc-tagged form. B. Consistent with this the 
inhibition of ATF6 reporter gene expression is reduced to a greater relative level by 
VAPBP56S-GFP than VAPBP56S-myc. 
Band intensities were determined using ImageJ (NIH) Intensities for  both myc 
and GFP, VAPB and VAPBP56S were normalised to the p38 loading control. 
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Figure 1A. 
 
 
 
Figure 1B 
 
 
 
 
 
Figure 1 C 
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Figure 3 
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Figure 6 
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